@article{10.37349/etat.2026.1002372,
abstract = {Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype defined by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2) expression. Consequently, standard hormone and HER2-targeted therapies are ineffective, necessitating reliance on chemotherapy, immunotherapy, antibody-drug conjugates (ADCs), and poly(ADP-ribose) polymerase (PARP) inhibitors for BRCA-mutated cases. TNBC exhibits rapid growth, a high risk of early recurrence, and disproportionately affects younger women, Black women, and BRCA1 mutation carriers. Standard management typically involves neoadjuvant chemotherapy followed by surgery and potential radiation. However, TNBC treatment remains challenging due to its severe biological heterogeneity, high metastatic potential, and the toxicity associated with systemic therapies. This review discusses the current understanding of TNBC biology, highlighting the urgent need for advanced diagnostics, integrated molecular subtyping, and personalized targeted therapies.},
author = {Alobaidi, Alhasan and Rai, Vikrant},
doi = {10.37349/etat.2026.1002372},
journal = {Exploration of Targeted Anti-tumor Therapy},
elocation-id = {1002372},
title = {Triple-negative breast cancer: current understanding and future perspectives},
url = {https://www.explorationpub.com/Journals/etat/Article/1002372},
volume = {7},
year = {2026}
}